The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Open accessAbstract
Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRAS G12C mutation who had been previously treated with other anticancer drugs.Methods We conducted a randomised, open-label phase 3 trial at 148 centres in 22 countries. We recruited patients aged at least 18 years with KRAS G12C-mutated advanced NSCLC, who progressed after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic driver mutation other than KRAS G12C for which an approved therapy is available (eg EGFR or ALK), previous treatment with docetaxel (neoadjuvant or adjuvant docetaxel was allowed if the tumour did not progress within 6 months after the therapy was terminated), previous treatment with a direct KRAS G12C inhibitor, systemic anticancer therapy within 28 days of study day 1, and therapeutic or palliative radiation therapy within 2 weeks of treatment initiation. We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m 2 once every 3 weeks) in an open-label manner using interactive response technology. Randomisation was stratified by number of previous lines of therapy in advanced disease (1 vs 2 vs >2), ethnicity (Asian vs non-Asian), and history of CNS metastases (present or absent). Treatment continued until an independent central confirmation of disease progression, intolerance, initiation of another anticancer therapy, withdrawal of consent, or death, whichever occurred first. The primary endpoint was progression-free survival, which was assessed by a blinded, independent central review in the intention-to-treat population. Safety was assessed in all treated patients. This trial is registered at ClinicalTrials.gov, NCT04303780, and is active but no longer recruiting.Findings Between June 4, 2020, and April 26, 2021, 345 patients were randomly assigned to receive sotorasib (n=171 [50%]) or docetaxel (n=174 [50%]). 169 (99%) patients in the sotorasib group and 151 (87%) in the docetaxel group received at least one dose. After a median follow-up of 17·7 months (IQR 16·4-20·1), the study met its primary endpoint of a statistically significant increase in the progression-free survival for sotorasib, compared with docetaxel (median progression-free survival 5·6 months [95% CI 4·3-7·8] vs 4·5 months [3·0-5·7]; hazard ratio 0·66 [0·51-0·86]; p=0·0017). Sotorasib was well tolerated, with fewer grade 3 or worse (n=56 [33%] vs n=61 [40%]) and serious treatment-related adverse events compared with docetaxel (n=18 [11%] vs n=34 [23%]). For sotorasib, the most common treatment-related adverse events of grade 3 or worse were diarrhoea (n= 20 [12%]), alanine aminotransferase increase (n=13 [8%]), and aspartate aminotransferase increase (n=9 [5%]). For docetaxel, the most common treatment-related adverse events of grade 3 or worse were neutropenia (n=13 [9%]), fatigue (n=9 [6%]), and febrile neutropenia (n=8 [5%]).Interpretation Sotorasib significantly increased progression-free survival and had a more favourable safety profile, compared with docetaxel, in patients with advanced NSCLC with the KRAS G12C mutation and who had been previously treated with other anticancer drugs.Funding Amgen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of multiple KRASG12C inhibitors have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite this success, disease progression occurs in many patients4,5,7, with development of resistance to KRASG12Ci recapitulated in preclinical studies9–11.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“while median overall survival was not improved with sotorasib compared with docetaxel (10.6 vs. 11.3 months; HR, 1.01) [25]”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“In the randomized phase III CodeBreaK 200 trial, sotorasib significantly improved progression-free survival compared with docetaxel in previously treated KRAS G12C-mutant NSCLC (median PFS, 5.6 vs. 4.5 months; HR, 0.66).”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [25]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, some patients selected for these trials may have preexisting multidrug resistance (9, 37, 74), which could contribute to treatment failure.”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [74]
Experimental — accuracy not yet measuredIn the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citationThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationFossella, F. V., DeVore, R. F., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L. A., Miller, V. A., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Self-citationFirst-Line Immunotherapy for Non–Small-Cell Lung Cancer
Reck, M., Remón, J., & Hellmann, M. D. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01497 · Cited by 909
Research works printed but not linked: 1
- Awad, 2022, Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): safety and efficacy data from the global expanded access program (EAP), Ann Oncol, 33, S448
Cited by
Sorted by citations
Items 501–600 of 619
Prise en charge du cancer pulmonaire non à petites cellules avec mutation de KRAS
Chour, A., Lafitte, C., Boussageon, M., Pierret, T., & Duruisseaux, M. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00078-3 · Cited by 1
Pathogenesis-based treatment strategies for brain metastases from non-small cell cancer
Iuchi, T., Shingyoji, M., Ashinuma, H., Mizuno, S., Hasegawa, Y., Setoguchi, T., Hosono, J., & Sakaida, T. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf155
Nakamura, T., Noda, S., Ooka, C., Takubo, Y., Noguchi, T., & Yasu, K. (2025) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.51.639
Advances in Systemic Therapy for Lung Cancer
Lalla, M., Pan, E., Jokić, V., Jeon, H., & Halmos, B. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.09.005
Therapie des metastasierten nichtkleinzelligen Lungenkarzinoms
Verheyen, M., Ruge, L., John, F., & Nogova, L. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01995-1
Speranza, D., Marafioti, M., Musarra, M., Cianci, V., Omero, F., Spagnolo, C. C., Calabrò, M., Silvestris, N., Irrera, N., & Santarpía, M. (2025) · Pharmaceuticals · doi:10.3390/ph18101574
Tomaschko, M., Ng, K., Moore, C., Pillsbury, C. E., Rana, S., Campbell, J., Mukherjee, S., Mikolajczak, A., Anastasiou, P., de Castro, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.27.684825
Structure-based design and synthesis of novel highly potent and selective KRASG12C inhibitors
Gao, K., Bao, L., Li, S., Zhang, C., Xu, L., & Zhu, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118321
Yang, X., Zhu, J., & Wu, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003878
Wang, L. (2025) · Transactions on Materials Biotechnology and Life Sciences · doi:10.62051/rq7x6r98
Trécesson, S. D. C., East, P., Pillsbury, C. E., dos Santos, M. S., Cha, H., Colliver, E., Gilmore, T., Rana, S., Moore, C., Lighterness, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690426
Gan, L., Shen, J., Yao, M.-X., Chen, Z., & Zhuang, Z. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i31.108942
Deciphering KRAS inhibitor resistance
Torphy, R. J., & Pylayeva‐Gupta, Y. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01757-z
Ratain, M. J., & Fojo, A. T. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01607
Liao, C., Wang, Y., Bi, Z., Chen, H., Xu, Y., Hu, D., Luo, R., Wang, J., Xu, Z. G., Li, Y., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101064
Self-citationActual possibilities of target therapy for Non-Small Cell Lung Cancer in Czech Republic
Bratová, M. (2025) · Onkologie · doi:10.36290/xon.2025.051
Lyu, M., Luo, L., Zhou, L., Feng, X., Yang, J. B., Ziwei, X. U., Sun, X., Bao, Z., Wang, X., 高蓓莉, et al. (2024) · Figshare · doi:10.6084/m9.figshare.25284799
Dang, S., Zhang, S., Zhao, J., & Li, W. (2024) · Figshare · doi:10.6084/m9.figshare.26308921
Revealing the Drivers Underlying Distinct Evolutionary Trajectories in Lung AdenocarcinomaPreprint
Wirth, C., Zhang, T., Díaz‐Gay, M., Steele, C. D., Hoang, P. H., Yang, Y., Khandekar, A., Zhao, W., Sang, J., Leduc, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.19.695410
Mita, A., Sakakibara, J., Kashima, M., Morinaga, D., Takahashi, H., Tagami, K., Shoji, T., Takashima, Y., Kitai, H., & Konno, S. (2025) · Haigan · doi:10.2482/haigan.65.1007
Shamsi, H. A., Abdelwahed, N., Jaafar, H., Ghazal, H., Kourié, H. R., Naim, N., Otsman, S., Bennini, N., Dawoud, E. A., Trad, D., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2610171
Self-citationRasoolzadeh, R., Faraji, H., Baptista, L., Vajedi, F. S., Nikoofard, V., da Costa, L. T., & Carneiro, J. W. D. M. (2026) · ACS Omega · doi:10.1021/acsomega.5c06228
Vinot, C., Ferté, C., Gaboriaud, T., Minvielle-Sebastia, A., Dubois, A., Schwob, R., Mallah, S., Pajiep, M., Alliot, J., Ferreira, A., et al. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100660
The current status of medicine development for precision therapy and diagnosis targeting KRASG12C
Zhang, C., Wang, F., & Tian, G.-L. (2026) · Biophysics Reports · doi:10.52601/bpr.2026.250060
Therapie des metastasierten nichtkleinzelligen Lungenkarzinoms
Verheyen, M., Ruge, L., John, F., & Nogová, L. (2026) · best practice onkologie · doi:10.1007/s11654-025-00709-1
Noordhof, A. L., Asmara, O. D., de Jong, K., Gijtenbeek, R. G. P., Huitema, Y. M., van Vollenhoven, F. H. M., Venmans, B. J. W., Hendriks, L. E. L., & van Geffen, W. H. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016054
Gentile, C., Feng, W. W., Lenahan, S. M., Ying, A. W., Card, D. C., Wu, F. T. H., Pham, N., Radulovich, N., Cao, P. M., Hueniken, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.27.708377
Su, Y., Wang, C., Sun, L., Jin, F., Wang, X., Wang, S., & Wang, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1795432
Morikawa, N., Mochizuki, S., & Suzuki, D. (2026) · International Journal of Lung Cancer · doi:10.1016/j.ijlcan.2026.100012
Spagnuolo, A., Spagnoletti, I., Nuccio, E., & Gridelli, C. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2636928
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153
Wang, J., Yan, Y., Su, Q., & Jia, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1776402
Zhang, Y., Zhao, J., Gao, Q., & Kong, M. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04475-5
Chen, R., Ma, Z., Yuan, M., Qian, K., & Zhu, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1784222
Sun, Y., Shi, H., & Lü, B. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156446
Molecular approaches to brain metastasis
Gritsch, D., Torrini, C., & Brastianos, P. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00015-2
Studiale, V., Taravella, A., Landi, M., Antoniotti, C., Botticelli, A., Marchetti, P., & Cremolini, C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103127
Innovative targeted therapies for mosaic RAS-related vascular malformations
Morin, G. (2024) · theses.fr (ABES) · doi:10.70675/88882e5fz1bf9z4dbezae13zba4200ee9598
KRAS inhibitors plus immunotherapy: Navigating efficacy, toxicity, and biomarkers
Ebi, H. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.107
Wang, J., Jiang, L.-L., Wang, M., & Li, Y.-L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s600434 · Cited by 1
MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
Román, S. D. H. (2023) · theses.fr (ABES) · doi:10.70675/8eaccae1ze96bz4279zb69fzaafa5e50c341
Toxicités cardiovasculaires des principales thérapies ciblées orales dans les tumeurs solides
Nannini, S., Droesch, C., Schultz, É., & Moinard‐Butot, F. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.02.014
Okazaki, Y., Yoshioka, H., Ikoma, T., Araki, K., Makihara, N., Kitagawa, M., Nagata, Y., Fujii, K., Okuno, Y., Kamisako, K., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101418
Weiss, G. J., Loftus, J. C., Mallery, D. W., & Tran, N. L. (2026) · Cancers · doi:10.3390/cancers18091367
Leonetti, A., Callegari, V., Perrone, F., Maglietta, G., Bordi, P., Bria, E., Vita, E., Gelsomino, F., Giglio, A. D., Gelibter, A., et al. (2026) · Tumori Journal · doi:10.1177/03008916261443123
Wu, Y. H., Zhang, L., Gui, J., Wang, J., Long, X., Lan, X., Lin, Y., & Cao, W. (2026) · Journal of Nuclear Medicine and Molecular Imaging · doi:10.65457/jnmmi-2026-0009
Metastasiertes nichtkleinzelliges Lungenkarzinom mit Treiberalterationen
Frille, A. (2026) · Zeitschrift für Pneumologie · doi:10.1007/s10405-026-00673-9
Targeting Complexity：Scientific Foundation and Frontiers of Multi-target Drug Discovery
Zhu, K., Wen, X., & Sun, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025.08.05.0004
Applications and Innovations in High-Throughput Sequencing: Thoracic Pathology
Perrone, G., & Nibid, L. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_6
Chen, J., Liu, X., Wang, R., Li, J., Xu, Z., Yang, B., He, Q., Yang, X., Yan, H., & Luo, P. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118078
Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma
Wilson, H. P., Stefanski, C. D., Caksa, S., Mersky, G. L., Varney, S. D., Haj, J. I., Erkes, D. A., Purwin, T. J., Chua, V., & Aplin, A. E. (2026) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70090
Nematzadeh, S., & Karaul, A. (2026) · Pharmaceuticals · doi:10.3390/ph19050748
Establishment of a Novel Anti-EphA4 Monoclonal Antibody, Ea 4 Mab-3, for Versatile Applications
Saga, A., Li, G., Tanaka, T., Kaneko, M. K., Suzuki, H., & Kato, Y. (2026) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1177/21679436261450334
Li, Y., Zhou, M., Pan, J., Su, H., Song, M., Guan, Z., Zhao, D., Zhao, X., Zhao, Y., Chen, P., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102821
Wang, X., & Yu, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1851178
Karim, N., Arnold, K. F., Summers, Y., Akram, T., Trankov, N., Vladimirova, A., Chopra, D., Mesa‐Frias, M., Waterhouse, D. M., & Stollenwerk, B. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109469
Self-citationAung, W. Y., Neumann, M., Wang, K. H., Chukkalore, D., Morales, J., & Seetharamu, N. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01315
Pisapia, P., Iaccarino, A., Luca, C. D., Pepe, F., Russo, G., Nacchio, M., Giovanni, D. D., Cozzolino, D., Conticelli, F., Palumbo, L., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04374-w
Huang, M., Yang, J., Peng, P., Wang, Y., Song, L., Lin, Y., & Zhao, J. (2026) · International Journal of Cancer · doi:10.1002/ijc.70545
Self-citationPedder, H., Manzano, C. L., Claxton, L., Whiting, P. F., Beggs, L., Sadek, A., Lokuge, K., Tomlinson, E., Cooper, C., James, R., et al. (2025) · Health Technology Assessment · doi:10.3310/gjnw3422
Karahan, L., Arslan, S., & Dızdar, Ö. (2026) · Cureus · doi:10.7759/cureus.110414
Tomaschko, M., Ng, K., Moore, C. L., Pillsbury, C. E., Rana, S., Campbell, J., Mukherjee, S., Mikolajczak, A., Anastasiou, P., de Castro, A., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5693
Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies
Jain, A., Rosell, R., Dharmashekara, C., Shreevatsa, B., González-Cao, M., Shivakumar, A., Kollur, S. P., Prasad, A., Shivamallu, C., & Prasad, M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05533-0
M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLSPreprint
Takamori, S., Haratake, N., Nonaka, K., Moriya, M., Bhattacharya, A., Takenaka, T., Yoshizumi, T., Long, M. D., & Kufe, D. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.20.733526
Ma, P., Zhou, Y., Zhang, X., Zhao, Q., Peng, Y., Jiang, H., Xie, L., & Liao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1808972
Kumar, M. D., & Kumar, S. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.23.734048
Therapeutic inhibition of RAS in non-small cell lung cancer
Nichols, K. B., & Herzberg, B. O. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1817943
Yifeng, L., Nanjo, S., Murase, Y., Arai, S., Watanabe, S., Tsuda, T., Suzuki, J., Taniguchi, H., Shibata, K., Sato, S., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03877-8
Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responder
Xu, J., Wang, S., Wang, Z. G., Huang, J., Xie, C., Zhao, T., Niu, Y., Cao, Y., Chen, M., & Leung, E. L. (2026) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2026.07.002
Aly, A. S., Yacoub, Z., & Yacoub, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10252473/v1
Yan, Y., Zheng, L., Wang, H., Sun, L., & Xu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848431
Molecular Subtypes of Cholangiocarcinoma and Their Translational Implications
Braconi, C., O’Rourke, C. J., Andersen, J., & Roberts, L. R. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.06.019 · Cited by 1
Din, S. M. U., Kiamos, A., Ali, S., Mehta, M. M., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146251
KRAS-mutated Non–Small Cell Lung Cancer
Saadany, T. E., Aeschlimann, N., & Sacher, A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000842
Nassar, A. H., Halawi, J., & Herbst, R. S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000834
Basic and Translational Research Advances in NSCLC
Sharma, R., & Politi, K. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000841
Management of brain metastases in older adults with non–small cell lung cancer
Lopes, J. B., Schep, D. G., Sahgal, A., Rodrigues, R. F., & Menjak, I. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1858724
Dorotenko, A. R., Shustova, M. S., Vlasenko, A. V., Kiselev, A. S., Blokhina, M., Moiseyenko, V. M., Zhukova, L., Stroyakovskiy, D., Breder, V. V., Феденко, А. А., et al. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2026.2.203748
Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation
Shen, L., Gao, Y., Song, Z., Wang, Q., Zhou, Q., Lei, Y., Lü, S., & Li, Z. (2026) · BMC Cancer · doi:10.1186/s12885-026-16643-6
Yuan, B., Zhang, Y., Li, X., Dong, Y., An, X., Jiao, T., Zhang, C., Chen, Y., Shi, J., Wu, S., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03858-1
Self-citationMasfarré, L., Parreira, A. S. D. F. M., Unanua, N. C., Miquel, C., Navarro-Gorro, N., Fabregat, R. M., Bellvert, C. G., Fernandez, A. A., Aguillo, M. M., Arasanz, H., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109560
Ikeda, S., Hasegawa, K., Takahama, T., Kachi, K., Yanagisawa, A., Kawakami, S., Yoshida, M., Sakai, M., Watanabe, S., & Nakagawa, K. (2026) · Cancer Science · doi:10.1111/cas.70499
Engineered caspases directly rewire mutant Ras to cell deathPreprint
Moeller, L., Lu, A. C., Ho, K., Zhang, E., & Elowitz, M. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743376
Salih, R., Sirajudeen, F., & Rahmani, M. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.030
Alonso-Alves, I., Conejo‐García, A., & Rubio‐Ruíz, B. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119225
The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives
Kim, B., Lee, G. T., Jeong, M., Choi, H., & Kim, K.-B. (2026) · iScience · doi:10.1016/j.isci.2026.117135
Jin, S., Zhang, Z., Liang, F., Yang, Y., Lü, A., & Liang, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00981-5
Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials
Li, R., Dong, X., Yao, X., Chen, W., An, H., & Li, Y. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00271
Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancer
Carvalho, G. D. S., Vianna, C. L., Wilheim, A., Santo, M. E., Milagres, R., Small, I. A., & Araujo, L. H. (2026) · BMC Cancer · doi:10.1186/s12885-026-16769-7
González, J., Cai, X., Diao, W., Roué, G., València-Clua, K., Olmo-González, D., González-Cao, M., Jain, A., Lewintre, E. J., Giménez-Capitán, A. A., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101351
Piekarz, J., Picheta, N., Pobideł, J., Gierulska, N., Kłodnicka, K., Januszewski, J., Szklener, K., & Skórzewska, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1916211
PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer
Lin, L., Moradi, N., Lähdeniemi, I. A. K., Laitinen, H. K., Alsaed, B., Lahtinen, L., Lopez, T., Jansouz, S., Knott, A., Soroko, K. M., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103002
Liu, D., Yang, X., Du, S., Sun, N., Lin, Y., Dong, Y., & Jiang, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177601
FOXD3 Is Functionally Linked to NF-κB Signaling in KRAS G12C-Mutant NSCLC Cells
Xu, P., Peng, J., Guo, C., Liu, Z., Cao, Y., Sheng, Q., Xu, W., & Li, X. (2026) · Cells · doi:10.3390/cells15171564
Sheffield, K. M., Puri, T., Thoele, K., Karu, H., Mansharamani, A., & Uprety, D. (2026) · Cancers · doi:10.3390/cancers18172869 · Cited by 1
Recent Advances in Targeted Therapies for Non-Small Cell Lung Cancer
张, 扬. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693077
Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?
Heynemann, S., Lipworth, W. L., McLachlan, S., Philip, J. A. M., John, T., & Kerridge, I. (2026) · Clinical Trials · doi:10.1177/17407745261469887
The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine
Gaździcka, J., & Gołąbek, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188194
Tsai, Y.-T., Hsu, W., & Chuang, C.-H. (2026) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-25-00040
Metadata
- Authors
- de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Yoneshima, Y., Kim, S.-W., Linardou, H., Novello, S., van der Wekken, A. J., Chen, Y., Peters, S., Felip, E., Solomon, B. J., Ramalingam, S. S., Dooms, C., Lindsay, C. R., Ferreira, C. G., Blais, N., Obiozor, C. C., Wang, Y., Mehta, B., Varrieur, T., Ngarmchamnanrith, G., Stollenwerk, B., Waterhouse, D., & Paz-Ares, L.
- Affiliations
- Sarah Cannon (US)
- Erasmus MC (NL)
- Henry Dunant Hospital (GR)
- Kantonsspital Winterthur (CH)
- University Hospital Cologne (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Kyushu University Hospital (JP)
- Asan Medical Center (KR)
- Metropolitan Hospital (GR)
- Ospedale San Luigi Gonzaga (IT)
- Centre Hospitalier Universitaire Vaudois (CH)
- Vall d'Hebron Hospital Universitari (ES)
- Peter MacCallum Cancer Centre (AU)
- Emory University (US)
- KU Leuven (BE)
- University of Manchester (GB)
- Centre Hospitalier de l’Université de Montréal (CA)
- Amgen (United States) (US)
- Amgen (Switzerland) (CH)
- Oncology Hematology Care (US)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Paz-Ares, Luis
- ORCID
- Johnson, Melissa L
- Dingemans, Anne-Marie C
- Mountzios, Giannis
- Pless, Miklos
- Wolf, Jürgen
- Skoulidis, Ferdinandos
- Yoneshima, Yasuto
- Kim, Sang-We
- Linardou, Helena
- Novello, Silvia
- Chen, Yuanbin
- Peters, Solange
- Felip, Enriqueta
- Solomon, Benjamin J
- Ramalingam, Suresh S.
- Dooms, Christophe
- Lindsay, Colin R
- Ferreira, Carlos Gil
- Blais, Normand
- Wang, Yang
- Stollenwerk, Björn
- Waterhouse, David
- Paz-Ares, Luis
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 401
- Issue
- 10378
- Pages
- 733-746
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4319337483
- Cited by
- 619
- References
- 29
- Citations by year
- 2026: 146 · 2025: 196 · 2024: 196 · 2023: 81
- FWCI
- 113.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Amgen
- Amgen Inc San Francisco
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- sotorasib, docetaxel, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, progression-free survival, second-line therapy, previously treated advanced NSCLC, central nervous system metastasis, treatment safety, oral versus intravenous administration, head-to-head comparison
- MeSH terms
- Docetaxel, Adolescent, Adult, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
